Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01749410 · ClinicalTrials.gov registry record
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 33
- Enrollment target
NCT01749410: Completed study, sponsored by Allergan.
NCT01749410 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01749410 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
Primary Outcome
The mean number of headache days was counted as the number of headache days occurring during the 30 day period ending with treatment cycle 7. Each treatment cycle was administered approximately every 12 weeks.
Interventions
- BIOLOGICAL onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-05 |
What the finished NCT01749410 record still lists
NCT01749410 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which onabotulinumtoxinA is the first listed.
NCT01749410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01749410 about?
NCT01749410 is a clinical study titled "A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines". This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
What is the current status of trial NCT01749410?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2013-05. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01749410?
The interventions under investigation include: onabotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT01749410?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia